Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Antisense Therapeutics Limited (“ANP” or “the Company”) is pleased to report the primary efficacy results from its phase 2 clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase 2 trial met its primary efficacy endpoint.
READ FULL ARTICLE
From News Medical
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Endocrinology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Endocrinology Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.